General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Underwriters in Keros Therapeutics’ Public Offering of Common Stock

November 13, 2020
Capital markets team represented the underwriters in the offering by the clinical-stage biopharmaceutical company.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, has announced the pricing of its public offering of 2,600,000 shares of common stock at a price to the public of $50.00 per share. The gross proceeds to Keros from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $130.0 million. All securities in the offering are being offered by Keros. In addition, Keros has granted the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on November 17, 2020, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by Boston partner Peter Handrinos and New York partner Nathan Ajiashvili, with New York associates Taylor Stevens and Daniel Walder.